Yongwei Hu, BON's CEO, stated, "Backed by the high druggability of our TCM-derived compound libraries and the efficiency of AI-powered screening technology, we are optimistic about Bon's potential to achieve meaningful breakthroughs in drug discovery. This initiative represents a strategic leap forward for our company and reinforces our long-term commitment to innovation in pharmaceutical research." XI'AN, China, July 30, 2025 /PRNewswire/ -- Bon Natural Life Limited (Nasdaq: BON) ("BON" or "the Company"), ...